5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02214862 (ClinicalTrials.gov) | March 2013 | 11/8/2014 | 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism | Progressive Supranuclear Palsy;Multi-System Atrophy;Parkinsonism | Drug: [F18]-FDDNP | Fundacion Clinic per a la Recerca Biomédica | NULL | Completed | 40 Years | N/A | Both | 40 | Phase 0 | Spain |